TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3471525

Group type: EXPERIMENTAL
Intervention: Aclarubicin, cytarabine and thioguanine (TAA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Daunorubicin, cytarabine and thioguanine (TAD)
Number of subjects: 23
Study: 30127510

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA) combined with working memory training (WMT) for 20 minutes, eight sessions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40
Study: 27517656

Group type: EXPERIMENTAL
Intervention: Perindopril 14mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Perindopril 20mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Perindopril 10-20mg
Number of subjects: 32
Study: 24898653

Group type: EXPERIMENTAL
Intervention: Nutritional intervention for 24 weeks
Number of subjects: 0
Study: 23729104

Group type: EXPERIMENTAL
Intervention: Surgery and radiotherapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Surgery, radiotherapy, and additional chemotherapy
Number of subjects: 26
Study: 20610445

Group type: EXPERIMENTAL
Intervention: Licofelone
Number of subjects: 161

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 161
Study: 18512224

Group type: EXPERIMENTAL
Intervention: Weekly regimen (paclitaxel 100 mg/m² weekly for 3 of 4 weeks; carboplatin AUC = 6 mg/mL.min every 4 weeks)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard regimen (paclitaxel 225 mg/m² every 3 weeks; carboplatin AUC = 6 mg/mL.min on Day 1 every 21 days)
Number of subjects: 136
Study: 15994082

Group type: EXPERIMENTAL
Intervention: Accelerated recovery protocol (Group A)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard care (Group S)
Number of subjects: 41
Study: 12495757

Group type: EXPERIMENTAL
Intervention: Painful heterotopic stimulation (cold pressor test, CPT)
Number of subjects: 12
Study: 10989734

Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg/day for 8 weeks, with the possibility to increase treatment to Fosinopril + hydrochlorothiazide after 4 weeks
Number of subjects: 1243

Group type: COMPARATOR
Intervention: Physicians aware of calculated cardiovascular risk
Number of subjects: 1243

Group type: COMPARATOR
Intervention: Physicians unaware of calculated cardiovascular risk
Number of subjects: 1243
Study: 8788082

Group type: EXPERIMENTAL
Intervention: Nicotine dermal plaster (21 mg/24 h or 14 mg/24 h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo dermal plaster
Number of subjects: 18
Study: 1634054

Group type: EXPERIMENTAL
Intervention: 800 mg 5-ASA three times daily (n = 64)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo (n = 61)
Number of subjects: 125
Study: 6229176

Group type: EXPERIMENTAL
Intervention: Vancomycin (15 mg/kg/dose)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 37
Study: 30126618

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (96 mg immediately after treatment followed by 48 mg each day for 5 consecutive days)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 125
Study: 26395742

Group type: EXPERIMENTAL
Intervention: Higher miR-27b
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Higher miR-320a
Number of subjects: 300
Study: 24692737

Group type: EXPERIMENTAL
Intervention: Pilocarpine (5 mg pilocarpine three times daily, n=5)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (saline solution intake, n=6)
Number of subjects: 11
Study: 23187989

Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope
Number of subjects: 23

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 23
Study: 20019680

Group type: EXPERIMENTAL
Intervention: Brief Counseling with medical assistants (8 visits over 6 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (quarterly PCP visits and weight loss materials)
Number of subjects: 50
Study: 18520796

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15788496

Group type: EXPERIMENTAL
Intervention: ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) plus sequential consolidation
Number of subjects: 647

Group type: COMPARATOR
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus involved-field radiotherapy
Number of subjects: 647
Study: 14575974

Group type: EXPERIMENTAL
Intervention: PCR testing for Borrelia sp
Number of subjects: 361
Study: 10826429

Group type: EXPERIMENTAL
Intervention: Bowel preparation with oral polyethylene glycol electrolyte solution
Number of subjects: 267

Group type: COMPARATOR
Intervention: No bowel preparation
Number of subjects: 267
Study: 8865111

Group type: EXPERIMENTAL
Intervention: Selenoprotein P
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Extracellular glutathione peroxidase (eGSHPx)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Plasma selenium
Number of subjects: 38
Study: 1641820

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg/24 h alteplase
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg/24 h alteplase
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control venogram
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Major bleeding incidents
Number of subjects: 32
Study: 6352952

Group type: EXPERIMENTAL
Intervention: Reading
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Relaxation exercises
Number of subjects: 19

Group type: COMPARATOR
Intervention: Maze-solving task
Number of subjects: 19
Study: 30644260

Group type: EXPERIMENTAL
Intervention: Short-segment fixation combined with vertebral reconstruction (treatment group)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Short-segment fixation (control group)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 30265043

Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Literature control condition
Number of subjects: 156
Study: 27247511

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 µg/kg IV loading dose followed by 0.5 µg/kg/hr infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (normal saline infusion)
Number of subjects: 60
Study: 24058179

Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 712

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 712
Study: 22310648

Group type: EXPERIMENTAL
Intervention: Use of standardized ECG criteria tool
Number of subjects: 60

Group type: COMPARATOR
Intervention: Baseline interpretation without standardized ECG criteria
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of cardiologists versus all other physicians
Number of subjects: 60
Study: 20872929

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg per day) for 24 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 42
Study: 18065586

Group type: EXPERIMENTAL
Intervention: Daily iron (DI) foodLETs (10 mg)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Daily multiple-micronutrients (DMM) foodLETs (10 mg Fe)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Weekly multiple-micronutrient (WMM) foodLETs (20 mg Fe)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Daily placebo
Number of subjects: 244
Study: 10832624

Group type: EXPERIMENTAL
Intervention: Gated magnetic resonance imaging (MRI) measuring early diastolic inflow velocity in the antero-posterior transverse direction of the LV.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gated magnetic resonance imaging (MRI) measuring early diastolic inflow velocity along the long axis of the LV.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group of age-matched healthy volunteers (10 subjects).
Number of subjects: 10
Study: 9174485

Group type: EXPERIMENTAL
Intervention: Reduced-fat foods (RF)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Reduced-sugar foods (RS)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 49
Study: 1371665

Group type: EXPERIMENTAL
Intervention: Aprotinin (total dose, 6 to 7 x 10(6) KIU)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 20
Study: 3083919

Group type: COMPARATOR
Intervention: 5 minute consultation interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7.5 minute consultation interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 minute consultation interval
Number of subjects: 0
Study: 30522524

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHP)
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (AA)
Number of subjects: 919

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: PRRD1 and PRRD2
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: PCT estimates from linear regression equations for PRRD1 and PRRD2
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: DHP treatment
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Age > 30 months, haematocrit ≥31%, body temperature > 37.4 °C, parasitaemia > 100,000/μl, PRRD1 value > 1000, no gametocytaemia
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: PCT estimates and PCTs determined by microscopy
Number of subjects: 919
Study: 27230605

Group type: EXPERIMENTAL
Intervention: nab-P/C (nab-paclitaxel 100 mg/m2 on days 1, 8, and 15 + carboplatin at AUC 6 mg·min/mL on day 1 every 3 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: sb-P/C (solvent-based paclitaxel 200 mg/m2 on day 1 + carboplatin at AUC 6 mg·min/mL on day 1 every 3 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: nab-P/C
Number of subjects: 61

Group type: COMPARATOR
Intervention: sb-P/C
Number of subjects: 61
Study: 25422587

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - 3 sessions of 30 minutes each over 6 weeks, n=26
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 54
Study: 22750166

Group type: EXPERIMENTAL
Intervention: Self-monitoring group (group A, n=63)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (group B, n=63)
Number of subjects: 126
Study: 20082723

Group type: EXPERIMENTAL
Intervention: Long symptom duration
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Worse KPS at baseline
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Gender, body mass index, arch height
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Age, worst pain, FIQ, step downs
Number of subjects: 179
Study: 19391466

Group type: EXPERIMENTAL
Intervention: Family group decision-making programs (FGDM)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Traditional services
Number of subjects: 110
Study: 15997202

Group type: EXPERIMENTAL
Intervention: Diet-Orlistat-Exercise (DOE) group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diet-Orlistat (DO) group
Number of subjects: 24
Study: 12808225

Group type: EXPERIMENTAL
Intervention: Combined training (aerobic + resistance)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 10577701

Group type: EXPERIMENTAL
Intervention: Accelerated regimen of 59.4 Gy, 1.8 Gy b.i.d over 24 days
Number of subjects: 191

Group type: COMPARATOR
Intervention: Conventional fractionation at 2 Gy/fraction per day, 70 Gy over 47 days
Number of subjects: 191
Study: 8699062

Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg 5 times/day) and prednisolone (0.7 mg/kg for the first 4 days, reduced by 0.1 mg/kg on consecutive days for another 6 days)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Acyclovir and prednisolone
Number of subjects: 94
Study: 1896168

Group type: EXPERIMENTAL
Intervention: Timolol (topical medication)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 0
Study: 31612327

Group type: EXPERIMENTAL
Intervention: A-PRF+
Number of subjects: 50

Group type: COMPARATOR
Intervention: No A-PRF+
Number of subjects: 50
Study: 31153846

Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable vascular scaffold (BVS)
Number of subjects: 2100

Group type: COMPARATOR
Intervention: Xience everolimus-eluting metallic stent (EES)
Number of subjects: 2100
Study: 28168204

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Conventional lifestyle intervention
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: 30 mg Pioglitazone
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study: 25526875

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg daily for 7 days, then 850 mg twice a day for the next 5 weeks
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo prescribed in a similar frequency
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 114

Group type: COMPARATOR
Intervention: Metformin and Placebo
Number of subjects: 114
Study: 23922647

Group type: EXPERIMENTAL
Intervention: ivacaftor (Kalydeco™; VX-770)
Number of subjects: 39

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study: 20972569

Group type: EXPERIMENTAL
Intervention: gadobutrol
Number of subjects: 40

Group type: COMPARATOR
Intervention: gadoterate meglumine
Number of subjects: 40
Study: 19298459

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-45 mg day(-1)) added to sulfonylurea
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-45 mg day(-1)) added to metformin
Number of subjects: 638

Group type: COMPARATOR
Intervention: Gliclazide (80-320 mg day(-1)) + metformin
Number of subjects: 638

Group type: COMPARATOR
Intervention: Gliclazide (80-320 mg day(-1)) + pioglitazone
Number of subjects: 638
Study: 17914131

Group type: EXPERIMENTAL
Intervention: MUFA-rich diet
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MUFA-rich breakfast
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-SAT breakfast
Number of subjects: 11

Group type: COMPARATOR
Intervention: CHO-rich breakfast
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: CHO-rich diet
Number of subjects: 11
Study: 16192421

Group type: EXPERIMENTAL
Intervention: High-dose hemodialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard-dose hemodialysis
Number of subjects: 0
Study: 12145995

Group type: EXPERIMENTAL
Intervention: 5'‐DFUR 600 mg/body/day for 6 months and TAM 20 mg/body/day for 2 years (Group A)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: 5'‐DFUR 600 mg/body/day for 2 years and TAM 20 mg/body/day for 2 years (Group B)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Radiotherapy (2 Gy x 5 times/week, for 5 weeks)
Number of subjects: 550
Study: 9988292

Group type: EXPERIMENTAL
Intervention: Family Visit Education Program (FVEP)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 66
Study: 7484859

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 12
Study: 1968323

Group type: EXPERIMENTAL
Intervention: atenolol 100 mg od
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: propranolol (slow release) 160 mg od
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: pindolol 5 mg tid
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: nebivolol 5 mg od
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study: 7295463

Group type: EXPERIMENTAL
Intervention: Labetalol (100 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30475424

Group type: EXPERIMENTAL
Intervention: F‐BFRE
Number of subjects: 14

Group type: COMPARATOR
Intervention: NF‐BFRE
Number of subjects: 14
Study: 27342579

Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide 1.0-3.0 g/day
Number of subjects: 549

Group type: COMPARATOR
Intervention: Sevelamer carbonate 2.4-14.4 g/day
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide
Number of subjects: 549

Group type: COMPARATOR
Intervention: Sevelamer carbonate
Number of subjects: 549
Study: 25584664

Group type: EXPERIMENTAL
Intervention: Multisector, multilevel intervention targeting improvements in fruit, vegetable, and water consumption; physical activity; and quality sleep.
Number of subjects: 1200
Study: 23692829

Group type: EXPERIMENTAL
Intervention: Intensive compact fluorescent tube (CFT) phototherapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intensive light-emitting diode (LED) phototherapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Both CFT and LED phototherapy
Number of subjects: 43
Study: 21849731

Group type: EXPERIMENTAL
Intervention: Stretching and strengthening exercises
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Scapular stabilization exercises
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Stretching and strengthening exercises)
Number of subjects: 40
Study: 19267352

Group type: EXPERIMENTAL
Intervention: Multi-peptide vaccination with 11 HLA‐A*0201‐restricted and two HLA class II synthetic peptides, administered subcutaneously for 18 months or until PSA progression, combined with various adjuvants including imiquimod, GM‐CSF, mucin‐1‐mRNA/protamine complex, and local hyperthermia.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Imiquimod and mucin‐1‐mRNA/protamine complex as adjuvants (both are Toll‐like receptor‐7 agonists).
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Multi-peptide vaccination
Number of subjects: 19
Study: 16696840

Group type: EXPERIMENTAL
Intervention: Real-world navigation
Number of subjects: 0
Study: 14759451

Group type: COMPARATOR
Intervention: Full-dose aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Half-dose aprotinin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study: 11725730

Group type: EXPERIMENTAL
Intervention: OC containing 0.030 mg of ethinyl estradiol (EE) and 0.15 mg of desogestrel (Group A)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: OC containing 0.020 mg of ethinyl estradiol (EE) and 0.15 mg of desogestrel (Group B)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 64
Study: 9164358

Group type: EXPERIMENTAL
Intervention: Salmeterol 42 micrograms twice daily
Number of subjects: 484

Group type: COMPARATOR
Intervention: Theophylline (extended-release)
Number of subjects: 484
Study: 8341090

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program for 3 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program
Number of subjects: 44
Study: 2959198

Group type: EXPERIMENTAL
Intervention: Teicoplanin regimen
Number of subjects: 47

Group type: COMPARATOR
Intervention: Amikacin plus ceftazidime
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Amikacin-ceftazidime-teicoplanin treatment
Number of subjects: 47
Study: 29221844

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 27342755

Group type: EXPERIMENTAL
Intervention: Virtual reality training curriculum for laparoscopic sigmoid colectomy (8 attempts of 3 modules or full procedure)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Virtual reality training curriculum for laparoscopic sigmoid colectomy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Benchmark criteria for experienced surgeons
Number of subjects: 33
Study: 24797423

Group type: EXPERIMENTAL
Intervention: 6 SQ‐HDM
Number of subjects: 604

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study: 22086747

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761® (240 mg once daily)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 20803423

Group type: EXPERIMENTAL
Intervention: Low-calorie meal replacement with mixed rice
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-calorie meal replacement with white rice
Number of subjects: 40
Study: 17961292

Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling for 30 min at 65 % of maximum heart rate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 12
Study: 15897360

Group type: EXPERIMENTAL
Intervention: Low mean arterial pressure (MAP) < or =92
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual MAP 102 to 107 mm Hg (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine (one of the antihypertensives)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramipril and Metoprolol (other antihypertensives)
Number of subjects: 0
Study: 12324674

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 400 micro g twice daily
Number of subjects: 259
Study: 10397653

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted inferior alveolar nerve block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional inferior alveolar nerve block
Number of subjects: 40
Study: 7595423

Group type: EXPERIMENTAL
Intervention: Snowman‐shaped outline with nine body parts read by an experimenter
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pointing to body parts on themselves
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Tadpole‐person drawers
Number of subjects: 28
Study: 2258518

Group type: EXPERIMENTAL
Intervention: Infection Control Liaison Nurse (ICLN) education and tutorials for ward nurses
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group with no ICLN involvement, only receiving in-service lectures from the Infection Control Nurse (ICN)
Number of subjects: 27
Study: 6103579

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 154

Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 154

Group type: COMPARATOR
Intervention: Cromoglycate
Number of subjects: 154
Study: 29063424

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 40
Study: 27389248

Group type: EXPERIMENTAL
Intervention: Patient-specific, evidence-based reminders generated by a multi-specialty decision support system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-specific, evidence-based reminders for venous thromboembolism (VTE) prevention
Number of subjects: 0